You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
個股熱度排行 | 2月23日港股盤前

根據uSMART輿情監測數據,從22日晚間到23日港股盤前時間段,市場關注指數最高的5只股票是匯豐控股、騰訊控股、新東方-S、百濟神州、新意網集團。

2月23日—港股關注排行TOP5

輿情變化榜單

匯豐控股

個股K線圖

關注度第一爲匯豐控股,該股上個交易日收盤下跌3.59%,報於56.45港元。近5個交易日累計下跌2.67%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

匯豐控股2月22日回購295.4萬股

匯控昨於倫敦回購逾295萬股 涉1,611萬英鎊

騰訊控股

個股K線圖

關注度第二爲騰訊控股,該股上個交易日收盤下跌0.13%,報於444.80港元。近5個交易日累計下跌5.36%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

港股通騰訊淨流出3.46億港元

應書嶺押寶英雄體育闖關港股,背靠騰訊爲何還越做越虧?

新東方-S

個股K線圖

關注度第三爲新東方-S,該股上個交易日收盤下跌4.46%,報於11.14港元。近5個交易日累計下跌4.13%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:

新東方-S中期淨虧損約9.08億美元

新東方半年鉅虧57億!俞敏洪發聲:不認輸…

百濟神州

個股K線圖

關注度第四爲百濟神州,該股上個交易日收盤下跌3.33%,報於124.90港元。近5個交易日累計下跌1.03%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

百濟神州:百悅澤獲美國食品藥品監督管理局受理治療慢性淋巴細胞白血病的新適應症上市許可申請

百濟神州:百悅澤® 獲美國FDA受理治療慢性淋巴細胞白血病的新適應症上市許可申請

新意網集團

個股K線圖

關注度第五爲新意網集團,該股上個交易日收盤下跌1.39%,報於7.09港元。近5個交易日累計下跌0.98%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:

新意網集團中期股東應佔溢利4.1億港元 同比增加5.6%

新意網集團中期股東應佔溢利同比增加5.6%至4.1億港元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account